NetworkNewsBreaks – Lexaria Bioscience Corp.’s
Post# of 721
(Total Views: 377)
Posted On: 01/25/2018 8:18:03 PM
NetworkNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH™ Platform Expands Portfolio
Food bioscience company Lexaria Bioscience’s (CSE: LXX) (OTCQB: LXRP) strategic focus for 2018 is on out-licensing its proprietary technology, DehydraTECH™. The company intends to out-license to third-party partners using a high margin royalty model. An article discussing the company’s drug delivery platform reads: “Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is a research-driven company that has developed and out-licenses a patented drug delivery platform called DehydraTECH™ that changes the way active pharmaceutical ingredients (“APIs”) enter the body orally. According to a new report by Million Insights (http://nnw.fm/1gI1m), the global API market is anticipated to reach $239.8 billion by 2025, with a CAGR of six percent. The rising prevalence of chronic health issues such as neurological and cardiovascular diseases are identified as growth factors.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Food bioscience company Lexaria Bioscience’s (CSE: LXX) (OTCQB: LXRP) strategic focus for 2018 is on out-licensing its proprietary technology, DehydraTECH™. The company intends to out-license to third-party partners using a high margin royalty model. An article discussing the company’s drug delivery platform reads: “Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is a research-driven company that has developed and out-licenses a patented drug delivery platform called DehydraTECH™ that changes the way active pharmaceutical ingredients (“APIs”) enter the body orally. According to a new report by Million Insights (http://nnw.fm/1gI1m), the global API market is anticipated to reach $239.8 billion by 2025, with a CAGR of six percent. The rising prevalence of chronic health issues such as neurological and cardiovascular diseases are identified as growth factors.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LXRPD) Stock Research Links
Scroll down for more posts ▼